See how patients feel about each treatment, and why
PatientlyIQ tracks how patients and caregivers talk about their treatments and the ones they compare them with. It links each opinion to its reason, such as side effects, cost, or access.
Treatments
- Leflunomide Positive
- Sulfasalazine Negative
Reasons
- Insurance Negative
- Finances Negative
- Access Negative
What you get
Sentiment by treatment
Positive and negative mentions for each treatment, with the quotes behind them.
The reasons behind it
See what drives sentiment, from side effects to cost, insurance, and access.
Competitor view
Follow competitor treatments, launches, and share of voice in patient conversations.
International sentiment
Compare how patients talk about treatments in different countries.
Line 1
Background therapy
| Drug | Approval | Class | Mentions | Sentiment | Top emotions |
|---|---|---|---|---|---|
Hydroxychloroquine (Plaquenil) | Approved | Antimalarial (immunomodulator) | 80 | Disappointment Hope Anxiety | |
ACE inhibitors / ARBs | n/a | ACE inhibitor / ARB (renin-angiotensin blocker) | 6 | Hope Pessimism Curiosity |
Line 2
Induction therapy for active nephritis
| Drug | Approval | Class | Mentions | Sentiment | Top emotions |
|---|---|---|---|---|---|
Corticosteroids (prednisone) | Approved | Corticosteroid | 140 | Disappointment Hope Sadness | |
Mycophenolate (CellCept / Myfortic) | Approved | Antimetabolite (IMPDH / purine inhibitor) | 105 | Acceptance Hope Apprehension | |
Cyclophosphamide (Cytoxan) | Approved | Alkylating agent | 25 | Hope Acceptance Disappointment | |
Belimumab (Benlysta) | Approved | Anti-BLyS / BAFF monoclonal antibody | 135 | Disappointment Hope Anxiety | |
Voclosporin (Lupkynis) | Approved | Calcineurin inhibitor | 7 | Optimism Hope Curiosity |
Line 3
Maintenance, refractory options, and advanced care
| Drug | Approval | Class | Mentions | Sentiment | Top emotions |
|---|---|---|---|---|---|
Azathioprine (Imuran) | Approved | Antimetabolite (IMPDH / purine inhibitor) | 25 | Disappointment Serenity Sadness | |
Rituximab (Rituxan) | Approved | Anti-CD20 monoclonal antibody | 19 | Optimism Anticipation Anxiety | |
Anifrolumab (Saphnelo) | Approved | Type-I interferon receptor antagonist | 43 | Disappointment Optimism Hope | |
Obinutuzumab (Gazyva) | Investigational | Anti-CD20 monoclonal antibody | 2 | Disappointment Hope | |
CAR-T therapy (investigational) | Investigational | Autologous CAR T-cell therapy | 105 | Hope Optimism Anticipation | |
Dialysis or kidney transplant | n/a | n/a | 23 | Despair Hope Confusion |
How it works
1.0
Find every mention
Posts, comments, videos, and podcasts that name a treatment.
2.0
Tag sentiment and reason
Each mention is tagged positive or negative, with the reason given.
3.0
Compare
Across treatments, competitors, countries, and time.
Questions it answers
- How do patients understand and judge a new therapy?
- Which treatment concerns and access barriers need a closer look?
- Where could positioning, education, or patient support better meet patient needs?
- How does treatment sentiment differ between countries?
Common questions
How we work, in detailFrom public patient and caregiver conversations on social media, patient communities such as PatientsLikeMe and Inspire, advocacy webinars and publications, and patient videos and podcasts. We also read search trends, competitor activity, and peer-reviewed research.
Yes. Upload patient, nurse, or site-staff interviews as audio or text. PatientlyIQ removes identifying details, splits each answer into quotes, and tags them the same way as the rest of the data.
With its theme, its sentiment, and the stage of the patient journey it describes. You can search and filter by all three.
Names and other identifying details are removed before a quote can be searched. The meaning of the quote stays.
Recurring executive reports every 30, 60, or 90 days, bespoke reports on a single question, or both. Your team can also search the quotes and export charts in the platform.
A bespoke report typically takes 12 to 20 business days from project confirmation, depending on scope.
Recurring reports are priced per month and bespoke reports per report. We agree the indication, topics, and measures with you first.
More use cases
Social Listening
Track what patients and caregivers say, and what changed since last month.
Learn MoreJourney Mapping
See the hurdles patients face at each stage, from first symptoms to the final study visit.
Learn MoreCompetitive Intelligence
See what competitors tell patients, and how patients respond.
Learn More
See PatientlyIQ on your indication
We will walk you through what patients and caregivers are saying in your therapeutic area.